A year ago, NBC News joined Wedam Minyila as he began undergoing a groundbreaking treatment for sickle cell disease. The ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...

Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted ...

Sickle cell disease (SCD) remains one of Uganda’s most silent epidemics, affecting thousands of children across the country, ...

Sickle cell anemia is the world's most common genetic disorder. It causes the red blood pigment hemoglobin to crystallize, ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Scientists already know that people with sickle cell traitare less likely to develop severe malaria. What has never been clear is whythis protection exists.One long-standing idea was that mosquitoes ...

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 ...

Minaris and Genetix Biotherapeutics have expanded their manufacturing partnership to increase commercial-scale production of ...

The mother of a four-year-old boy with a rare muscle disease says screening newborn babies for the condition could "save ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...